Renaissance Technologies LLC has recently announced that it has increased stake in Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) by 17.88%. After grabbing 25370.0 shares, the institutional investor is now in possession of 3848.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 1.11% having worth around $38816.0. Moreover, Horizon Kinetics Asset Management increased its share by 800.0 to have a control over 2400.0 shares.
Salarius Pharmaceuticals Inc. (SLRX) concluded trading on 01/19/23 at a closing price of $3.58, with 3.58 million shares of worth about $12.81 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -27.42% during that period and on Thursday the price saw a gain of about 52.99%. Currently the company’s common shares owned by public are about 2.25M shares, out of which, 2.17M shares are available for trading.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 1 analysts are covering the SLRX stock and their offered price forecasts bring an average price target of $125.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $125.00 and could fall to a lowest price of $125.00. The stock’s current price level is 94.92% above of average price target set by the analysts, while a rise to estimated low would result in gain of 97.14% for the stock. However, touching the estimated high of $125.00 would mean a gain of 97.14% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 19 times over the past 12 months. They bought 456,196 shares in 19 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
FCP Medical – BioHealth, Vanguard Total Stock Market Index, and Vanguard Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Salarius Pharmaceuticals Inc. FCP Medical – BioHealth is currently holding 55502.0 shares of worth totaling $84918.0. The company recently came buying 0.0 shares which brought its stake up to 2.44% of the company’s outstanding shares. Vanguard Extended Market Index Fu, after buying 15113.0 shares, have now control over 0.66% of the stake in the company. It holds 0.0 shares of worth $23123.0.
However, the stock later moved at a day high price of 4.1000, or with a gain of 52.99%. Stock saw a price change of 62.73% in past 5 days and over the past one month there was a price change of 138.67%. Year-to-date (YTD), SLRX shares are showing a performance of 133.99% which decreased to -69.68% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.07 but also hit the highest price of $13.46 during that period. The average intraday trading volume for Salarius Pharmaceuticals Inc. shares is 60.15K. The stock is currently trading 103.41% above its 20-day simple moving average (SMA20), while that difference is up 96.02% for SMA50 and it goes to -19.23% lower than SMA200.
Renaissance Technologies LLC acquired 25370.0 shares of Salarius Pharmaceuticals Inc. having value of about $38816.0. Data submitted at the U.S SEC by Renaissance Technologies LLC revealed that the firm now holds 3848.0 shares in the company valued at close to $13775.84, or have control over 17.88% stake in the company. Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) currently have 2.25M outstanding shares and institutions hold larger chunk of about 16.30% of that. Holding of mutual funds in the company is about 5.88% while other institutional holders and individual stake holders have control over 9.38% and 2.91% of the stake respectively.
The stock has a current market capitalization of $8.23M and its 3Y-monthly beta is at 0.67. It has posted earnings per share of -$14.18 in the same period. It has Quick Ratio of 5.80 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SLRX, volatility over the week remained 32.37% while standing at 18.66% over the month.
Analysts are in expectations that Salarius Pharmaceuticals Inc. (SLRX) stock would likely to be making an EPS of -$2.55 in the current quarter, while forecast for next quarter EPS is -$1.9 and it is -$9.6 for next year. For the current quarter EPS, analysts have given the company a lowest target -$2.85 which is -$2.25 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$2 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 37.90% while it is estimated to increase by 34.30% in next year.
Analysts at 1 brokerage firms have issued recommendations for the Salarius Pharmaceuticals Inc. (SLRX)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 1 Wall Street analysts, 1 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Ladenburg Thalmann on April 27, 2020 offering a Buy rating for the stock and assigned a target price of $3.80 to it.
